Any BioTech Guys that Have Looked at Moderna?

I am not a biotech person, looking at Moderna. Has any looked at Moderna as a possible long or short? Why was it USED for such an IMPORTANT pandemic? Specifically trying to get comfortable with the following qs: 

1. Which of their drugs in-development are first-in-class drugs? What is generally the decision-framework behind allocating capital to these? 

2. How does one think through their scientist research and your scientist-retention ratio? What is the best way to measure productivity? Is it increase (%) in R&D relative to the % # of drugs that pass onto the next phase?    

3. I am looking at their teams' cost-base in relation to Pfitzer (much larger company, granted), and using your SG&A expense as a proxy for fixed costs including non R&D salaries, I see the average cost / employee is $110K compared to $73K for Pfitzer. I understand earlier years may be spent burning cash, but Moderna has been around for 10+ years now. How do I justify these to myself? 

4. Related to the above note, for the senior management, how is the payout determined? What factor does R&D pipeline achievement play in that?     

5. With respect to its revenue split, how should one think about it from Government Contracts, and Grant perspective, and which r assets have licensing potential i.e. ability to earn royalties? 

6. Their revenue for 9M 21 was about $11.3 billion, of which 75% is in deferred revenue. What would be the cost of servicing this revenue? Is it non-material?

7. I am not a fan of DCFs, particularly over a long time frame. It's like coming up with something out of your ass when you have no idea what will transpire over the future. What's a better valuation metric to value biotech?

8. For those of you with non science backgrounds, how did you get comfortable "understanding the science"?

Let me know pls. thx 

2 Comments
 
 

Sint quae quis expedita atque. Animi alias nisi autem incidunt repellat aut et. Deleniti eos molestiae est dolores et iste. Laborum recusandae numquam officiis. Aperiam esse ut et.

Nobis beatae et qui et aut quia fugiat. Sed eos soluta distinctio sit et ipsam. Ex fuga et animi delectus explicabo consectetur. Aut quidem illo quidem unde excepturi et id. Est soluta fugit voluptatibus dolorem quia sed in cumque.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (68) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
DrApeman's picture
DrApeman
98.9
6
CompBanker's picture
CompBanker
98.9
7
dosk17's picture
dosk17
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
GameTheory's picture
GameTheory
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”